Chemotherapy Induced Nausea and Vomiting (CINV) are the side effects of cancer chemotherapy that can cause significant negative impacts on patients’ quality of life and on their ability to tolerate and comply with therapy. An estimated 80% of patients with cancer experience chemotherapy-induced nausea and vomiting. It includes emesis and nausea, which can involve a loss of appetite and result in decreased oral intake of fluids and calories. CINV can be classified into 5 types: acute, delayed, anticipatory, breakthrough, and refractory. The pathophysiology of CINV includes both peripheral and central nervous system (CNS) pathways with different mechanisms involved in acute CINV and delayed CINV. Risk factors for developing CINV can be classified as patient-related or treatment-related. Prevention is the primary goal in the management of CINV. The primary alternative for prevention and treatment include 5-HT3 receptor antagonists, NK1 receptor antagonists, and corticosteroids. Other medications used, but to a lesser extent, include dopamine antagonists, benzodiazepines, cannabinoids, and olanzapine.
DelveInsight’s, “Chemotherapy Induced Nausea and Vomiting Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Chemotherapy Induced Nausea and Vomiting pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Some of Chemotherapy Induced Nausea and Vomiting Companies are:
- Acacia Pharma
- Camurus
- LP Pharmaceuticals
- Skye Bioscience
- TALLC Corporation
- Starton Therapeutics
- And Many Others
Request for Free Sample Page: https://www.delveinsight.com/sample-request/chemotherapy-induced-nausea-and-vomiting-pipeline-insight
DelveInsight’s Chemotherapy Induced Nausea and Vomiting report covers around 15+ products under different phases of clinical development like:
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Some of Chemotherapy Induced Nausea and Vomiting Therapies are:
- APD403
- CAM2047
- TA-A002
- And Many Others
Request for Free Sample Page: https://www.delveinsight.com/sample-request/chemotherapy-induced-nausea-and-vomiting-pipeline-insight
Current Chemotherapy Induced Nausea and Vomiting Treatment Scenario and CINV Emerging Therapies:
- How many companies are developing Chemotherapy Induced Nausea and Vomiting drugs?
- How many Chemotherapy Induced Nausea and Vomiting drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chemotherapy Induced Nausea and Vomiting?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chemotherapy Induced Nausea and Vomiting therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Chemotherapy Induced Nausea and Vomiting and their status?
- What are the key designations that have been granted to the emerging drugs?
Request for Free Sample Page: https://www.delveinsight.com/sample-request/chemotherapy-induced-nausea-and-vomiting-pipeline-insight
Table of Contents:
Introduction
Executive Summary
Chemotherapy Induced Nausea and Vomiting: Overview
Pipeline Therapeutics
Therapeutic Assessment
Chemotherapy Induced Nausea and Vomiting – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Chemotherapy Induced Nausea and Vomiting Collaboration Deals
Late Stage Products (Phase III)
Drug name: Company name
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
APD403: Acacia Pharma
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
CAM2047: Camurus
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
TA-A002: TALLC Corporation
Drug profiles in the detailed report…..
Inactive Products
Chemotherapy Induced Nausea and Vomiting Key Companies
Chemotherapy Induced Nausea and Vomiting Key Products
Chemotherapy Induced Nausea and Vomiting- Unmet Needs
Chemotherapy Induced Nausea and Vomiting- Market Drivers and Barriers
Chemotherapy Induced Nausea and Vomiting- Future Perspectives and Conclusion
Chemotherapy Induced Nausea and Vomiting Analyst Views
Chemotherapy Induced Nausea and Vomiting Key Companies
Appendix
Request for Detailed TOC: https://www.delveinsight.com/sample-request/chemotherapy-induced-nausea-and-vomiting-pipeline-insight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/chemotherapy-induced-nausea-and-vomiting-pipeline-insight